In a hepatoma mouse model, combination treatment of anti-PD-1 antibodies with anti-IL-1β antibodies or the PIM inhibitor AZD1208 led to complete tumor regression [76]. This evidence concerns the gene IL1B and hepatocellular carcinoma.